Cowen analyst Phil Nadeau reiterated an Outperform rating on Achillion Pharmaceuticals (NASDAQ: ACHN) following the HCV deal with JNJ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE